Eledon Pharmaceuticals, Inc.

Listed Company

ELDNCIK 0001404281NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-45.60M

Total Assets

$169.01M

Equity

$81.08M

Shares Out

75.85M

Op. Cash Flow

$-62.34M

Business

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunomodulatory therapies that target the CD40 Ligand (CD40L) pathway, with a primary focus on tegoprubart to protect transplanted organs and treat ALS. Its main product is tegoprubart, an engineered anti-CD40L IgG1 antibody under clinical development for kidney allograft prevention, xenotransplantation, islet cell transplantation, and ALS (IgAN deprioritized). The company operates research and development, clinical programs, intellectual property management, and third-party manufacturing partnerships. Eledon conducts clinical trials and seeks regulatory approvals across the United States, Canada, the United Kingdom, Australia and other international markets through investigator-initiated studies and collaborative arrangements.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	66	52	30	27	24
General and administrative	17	19	13	13	13
Total operating expenses	83	71	43	88	37
Other income, net	4	4	3	462,000	7,000
Change in fair value of warrant liabilities	33	31	—	—	—
Loss before income taxes	−46	−36	−117	−88	−37
Provision for income taxes	−35,000	−431,000	0	0	2
Net loss	−46	−36	−117	−88	−35
Unrealized loss on available-for-sale securities, net	−2,000	—	—	—	—
Comprehensive loss	−46	−36	—	—	—
Basic earnings per share of common stock	−0.52	−0.66	−4.73	−6.16	−2.33
Diluted earnings per share of common stock	−0.52	−0.66	−4.73	−6.16	−2.33
Weighted-average common shares outstanding, basic	82	49	25	14	15
Weighted-average common shares outstanding, diluted	82	49	25	14	15

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	23	21	5	56	85
Short-term investments	111	120	46	0	—
Prepaid expenses and other current assets	2	4	5	3	4
Total current assets	136	144	56	60	88
Operating lease right-of-use asset, net	613,000	926,000	365,000	739,000	768,000
In-process research and development	32	32	32	32	32
Other assets	322,000	363,000	186,000	150,000	400,000
Total assets	169	177	89	93	171
Accounts payable	4	6	967,000	2	2
Current operating lease liability	358,000	314,000	383,000	363,000	369,000
Accrued expenses and other liabilities	14	5	3	4	2
Total current liabilities	18	12	4	6	4
Deferred tax liability	2	2	2	2	2
Non-current operating lease liability	283,000	640,000	0	383,000	400,000
Warrant liabilities	11	45	76	—	—
Total liabilities	32	59	82	9	7
Commitments and contingencies (Note 7)	—	—	—	—	—
Common stock, $0.001 par value, 300,000,000 and 200,000,000 shares authorized at December 31, 2025 and 2024, respectively; 75,430,033 and 59,789,275 shares issued and outstanding at December 31, 2025 and 2024, respectively	75,000	60,000	24,000	14,000	14,000
Additional paid-in capital	482	418	327	287	279
Accumulated other comprehensive income	24,000	26,000	—	—	—
Accumulated deficit	−401	−356	−319	−203	−115
Total stockholders' equity	81	62	−48	84	164
Total liabilities, convertible preferred stock and stockholders' equity	169	177	89	93	171

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Gain on lease termination	—	−10,000	—	—	—
Non-cash lease expense	313,000	359,000	—	—	—
Accretion of investment discounts	−2	−3	−1	—	—
Stock-based compensation	10	13	7	8	8
Deferred tax provision	5,000	431,000	—	—	—
Prepaid expenses and other assets	1	1	−2	654,000	−2
Accounts payable, accrued expenses and other liabilities	7	8	−3	2	—
Operating lease liabilities	−313,000	−339,000	−363,000	−367,000	−200,000
Net cash used in operating activities	−62	−47	−40	−28	−29
Purchase of available-for-sale short-term investments	−161	−156	−78	—	—
Proceeds from maturities of available-for-sale short-term investments	172	86	33	—	—
Net cash provided by (used in) investing activities	11	−70	−45	—	—
Proceeds from issuances of common stock and pre-funded warrants, net	54	133	33	—	—
Proceeds from exercise of stock options	230,000	215,000	—	—	1,000
Net cash provided by financing activities	54	134	33	—	−449,000
Net change in cash and cash equivalents	2	16	−52	−28	−29
Unrealized gain (loss) on available-for-sale securities	−2,000	26,000	—	—	—
Common stock exchange for warrants	4,000	—	—	—	1,000
Offering costs accrued but not yet paid	4,000	—	—	—	—
Increase in operating right-of-use lease asset and liability due to new lease	—	920,000	—	—	—
Settlement of warrant liability into common stock due to exercise	—	446,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro